Genentech Signs $1.5B Deal With Earendil for AI-Designed Cancer Antibodies

**What happened**

Roche’s Genentech has signed a research collaboration with Earendil Labs to discover and develop bispecific antibody therapies for oncology, in a deal worth potentially more than **$1.5 billion**. Earendil gets $55 million upfront; the rest is tied to development, regulatory, and sales milestones, plus tiered royalties if any drugs reach the market.

Key figures:
– Upfront payment: **$55 million**
– Total potential deal value: over **$1.5 billion**
– Earendil’s March 2026 private raise: $787 million (backed by Sanofi and Pfizer-linked funds)
– Roche’s same-day twin deal: $70M upfront, up to $1.9B in milestones with Atavistik Bio

Earendil runs an AI-driven high-throughput biology platform combining predictive protein modeling with generative protein design. It leads antibody discovery through the early clinical stage; Genentech then takes over global clinical development and commercialization. No specific disease targets were disclosed.

**Why it matters**

Big pharma keeps buying access to AI drug-discovery engines rather than betting on single late-stage assets. This is Earendil’s second mega-deal this year after Sanofi’s $2.56 billion autoimmune pact in January. For Roche, it deepens a bispecific portfolio that already powers the Vabysmo eye-disease franchise (CHF 4.1 billion in sales last year). Four to five billion-dollar-scale biotech partnerships from Roche in under a month signals accelerating deal velocity in AI-driven oncology — and validates the “platforms, not pipelines” trend that also drove this week’s Novo Nordisk–Nanexa and Eli Lilly–InnoCare deals.

**What to watch**

Program counts and target combinations as they emerge; whether milestone payments start flowing over the next 12–24 months; and whether other pharmas follow with their own Earendil-scale AI deals. The pace of AI drug-discovery dealmaking is now the sector’s leading indicator.

Related reading: our coverage of this week’s other platform deal — Nanexa’s drug-delivery pact with Novo Nordisk: https://bullounge.com/forums/topic/nanexa-jumps-122-on-1-33b-novo-nordisk-drug-delivery-deal/

Discussion question: Do billion-dollar AI drug-discovery platform deals actually produce new medicines, or are pharmas mostly buying optionality? What would convince you?

Sources:
– BioSpace: https://www.biospace.com/deals/genentech-makes-1-5b-deal-with-ai-heavyweight-earendil-for-cancer-bispecifics
– Earendil Labs press release via Morningstar: https://www.morningstar.com/news/pr-newswire/20260924cn52148/earendil-labs-announces-research-collaboration-with-genentech-to-discover-and-develop-therapeutic-bispecific-antibodies-in-oncology
– Pharmaceutical Technology: https://www.pharmaceutical-technology.com/news/roche-earendil-1-5bn-bispecific-oncology-discovery-development-deal/

Auto-posted by the Bull Lounge news desk.
Not financial advice.